Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MDAI NYSE:MLSS NASDAQ:OSRH NASDAQ:PSTV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMDAISpectral AI$1.94-2.5%$2.31$0.82▼$3.25$53.20M0.88260,693 shs245,084 shsMLSSMilestone Scientific$0.59$0.60$0.38▼$1.39$46.35M0.94200,729 shs43,232 shsOSRHOSR$0.62+1.7%$0.80$0.45▼$13.40$13.17M1.5113.96 million shs199,837 shsPSTVPlus Therapeutics$0.45-4.8%$0.50$0.16▼$2.31$46.65M0.666.27 million shs5.04 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMDAISpectral AI0.00%+6.59%-7.62%-1.52%+48.09%MLSSMilestone Scientific0.00%-4.39%+1.86%-32.95%-38.86%OSRHOSR0.00%+7.84%+19.00%-56.02%+62,009,900.00%PSTVPlus Therapeutics0.00%-8.97%-17.50%+42.45%-66.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMDAISpectral AI$1.94-2.5%$2.31$0.82▼$3.25$53.20M0.88260,693 shs245,084 shsMLSSMilestone Scientific$0.59$0.60$0.38▼$1.39$46.35M0.94200,729 shs43,232 shsOSRHOSR$0.62+1.7%$0.80$0.45▼$13.40$13.17M1.5113.96 million shs199,837 shsPSTVPlus Therapeutics$0.45-4.8%$0.50$0.16▼$2.31$46.65M0.666.27 million shs5.04 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMDAISpectral AI0.00%+6.59%-7.62%-1.52%+48.09%MLSSMilestone Scientific0.00%-4.39%+1.86%-32.95%-38.86%OSRHOSR0.00%+7.84%+19.00%-56.02%+62,009,900.00%PSTVPlus Therapeutics0.00%-8.97%-17.50%+42.45%-66.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMDAISpectral AI 3.00Buy$3.5080.41% UpsideMLSSMilestone Scientific 3.00Buy$1.25111.86% UpsideOSRHOSR 0.00N/AN/AN/APSTVPlus Therapeutics 3.20Buy$7.881,660.56% UpsideCurrent Analyst Ratings BreakdownLatest OSRH, PSTV, MLSS, and MDAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025PSTVPlus TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/3/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$5.008/18/2025PSTVPlus TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.00 ➝ $3.006/27/2025PSTVPlus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.50 ➝ $3.006/25/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$9.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMDAISpectral AI$27.55M1.88N/AN/A($0.32) per share-6.06MLSSMilestone Scientific$9.08M5.10N/AN/A$0.11 per share5.36OSRHOSRN/AN/AN/AN/A($3.87) per shareN/APSTVPlus TherapeuticsN/AN/AN/AN/A($1.52) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMDAISpectral AI-$15.31M-$0.69N/AN/AN/A-51.97%N/A-8.69%11/5/2025 (Estimated)MLSSMilestone Scientific-$6.93M-$0.09N/A∞N/A-52.01%-60.26%-40.23%N/AOSRHOSR-$2.41MN/A0.00∞N/AN/A-12.19%-8.18%N/APSTVPlus Therapeutics-$12.98M-$2.24N/AN/AN/A-357.85%N/A-117.72%11/13/2025 (Estimated)Latest OSRH, PSTV, MLSS, and MDAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025OSRHOSRN/A$0.02N/A$0.02N/A$1.14 million8/14/2025Q2 2025PSTVPlus Therapeutics-$0.09-$0.01+$0.08-$0.01$1.08 million$1.39 million8/12/2025Q2 2025MDAISpectral AI-$0.07-$0.10-$0.03-$0.31$5.44 million$5.07 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMDAISpectral AIN/AN/AN/AN/AN/AMLSSMilestone ScientificN/AN/AN/AN/AN/AOSRHOSRN/AN/AN/AN/AN/APSTVPlus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMDAISpectral AIN/A0.870.84MLSSMilestone ScientificN/A2.851.86OSRHOSRN/A0.180.17PSTVPlus TherapeuticsN/A1.261.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMDAISpectral AI67.08%MLSSMilestone Scientific5.79%OSRHOSR55.30%PSTVPlus Therapeutics3.28%Insider OwnershipCompanyInsider OwnershipMDAISpectral AI30.70%MLSSMilestone Scientific24.75%OSRHOSR60.60%PSTVPlus Therapeutics0.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMDAISpectral AI8326.73 million18.53 millionNot OptionableMLSSMilestone Scientific3078.56 million58.61 millionOptionableOSRHOSRN/A21.58 million8.50 millionN/APSTVPlus Therapeutics2099.27 million98.48 millionNot OptionableOSRH, PSTV, MLSS, and MDAI HeadlinesRecent News About These CompaniesHead to Head Analysis: Plus Therapeutics (NASDAQ:PSTV) and Gain Therapeutics (NASDAQ:GANX)September 8, 2025 | americanbankingnews.comD Boral Capital Upgrades Plus Therapeutics (NASDAQ:PSTV) to Strong-BuySeptember 5, 2025 | americanbankingnews.comPlus Therapeutics (NASDAQ:PSTV) Upgraded by D. Boral Capital to Buy RatingSeptember 4, 2025 | americanbankingnews.comPlus Therapeutics upgraded to Buy from Hold at D. Boral CapitalSeptember 3, 2025 | msn.comD. Boral Capital Upgrades Plus Therapeutics (PSTV)September 3, 2025 | msn.comPlus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | finance.yahoo.comPlus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | globenewswire.comPlus Therapeutics Secures Nasdaq Compliance ExtensionAugust 26, 2025 | msn.comPlus Therapeutics, Inc. Confirms Compliance with Nasdaq Listing Rules Ahead of Grace Period ExpirationAugust 26, 2025 | quiverquant.comQPlus Therapeutics Regains Compliance with Applicable Nasdaq Listing CriteriaAugust 26, 2025 | globenewswire.comPlus Therapeutics (NASDAQ:PSTV) Director Acquires $53,900.00 in StockAugust 26, 2025 | insidertrades.comPlus Therapeutics price target lowered to $3 from $4 at MaximAugust 19, 2025 | msn.comPlus Therapeutics presents results from ReSPECT-LM Phase 1 trialAugust 19, 2025 | msn.comPlus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal MetastasesAugust 18, 2025 | globenewswire.comPlus Therapeutics Reports Strong Q2 2025 ResultsAugust 16, 2025 | msn.comPlus Therapeutics Reports $3M in Stock EquityAugust 16, 2025 | baystreet.caPlus Therapeutics Reports $3M in Stock EquityAugust 16, 2025 | baystreet.caPlus Therapeutics reports stockholders’ equity in excess of $2.5MAugust 16, 2025 | msn.comPlus Therapeutics reports stockholders’ equity in excess of $2.5MAugust 16, 2025 | msn.comPlus Therapeutics Reports Stockholders’ Equity in Excess of $2.5 million in Compliance with Nasdaq Equity RequirementsAugust 16, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOSRH, PSTV, MLSS, and MDAI Company DescriptionsSpectral AI NASDAQ:MDAI$1.94 -0.05 (-2.51%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.96 +0.03 (+1.29%) As of 09/12/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.Milestone Scientific NYSE:MLSS$0.59 0.00 (-0.34%) As of 09/12/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Milestone Scientific Inc., a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. In addition, the company offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances, and disposable injection handpiece for the tactile control during the injection. Further, it provides CompuFlo Epidural, a computer-controlled anesthesia system for use in various medical applications. Additionally, the company offers company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Roseland, New Jersey.OSR NASDAQ:OSRH$0.62 +0.01 (+1.66%) As of 09/12/2025 03:59 PM EasternOSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.Plus Therapeutics NASDAQ:PSTV$0.45 -0.02 (-4.81%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.45 0.00 (-0.07%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
